OrthoPediatrics Corp. (NASDAQ: KIDS) is a medical device company focused exclusively on the pediatric orthopedic market. It designs and sells implants and instruments for children with orthopedic conditions. The company recently expanded its portfolio with the TRAXIO Halo Gravity Traction System, as highlighted by GlobeNewswire, to help with spinal realignment in young patients.
On April 30, 2026, OrthoPediatrics Corp. reported its first-quarter earnings results. The company announced an earnings per share (EPS) of -$0.45. This figure narrowly beat analyst estimates of -$0.46. EPS represents the portion of a company's profit allocated to each share of stock, with a negative number indicating a net loss for the period.
The company also posted revenue of $59.36 million, which was higher than the estimated $58.29 million. This total revenue marks a 13% increase from the $52.40 million reported in the first quarter of 2025. Growth was driven by an 11% increase in domestic revenue and a 22% increase in international revenue.
Despite the net loss, some metrics show operational improvement. The company's adjusted EBITDA, which measures earnings before interest, taxes, depreciation, and amortization, was $2.20 million. This is a significant improvement from a loss of $0.40 million in the same period last year. The company also reduced its free cash flow usage by 40%.
From a valuation standpoint, OrthoPediatrics Corp. has a Price-to-Sales ratio of 1.56. This ratio compares the company's stock price to its revenues. The company's negative Price-to-Earnings (P/E) ratio of -8.99 reflects its current lack of profitability. However, it maintains a low Debt-to-Equity ratio of 0.14 and a strong current ratio of 5.21.
